Inclisiran for Hypercholesterolemia
(ORION-19 Trial)
Trial Summary
What is the purpose of this trial?
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).
Will I have to stop taking my current medications?
No, you won't have to stop your current medications. Participants must stay on a stable dose of their lipid-lowering therapies, like statins or ezetimibe, for at least 30 days before the trial and continue without changes during the study.
What data supports the effectiveness of the drug Inclisiran for treating hypercholesterolemia?
Research shows that Inclisiran effectively lowers LDL cholesterol (a type of bad cholesterol) by about 50% in patients with high cholesterol, even when they are already on other cholesterol-lowering medications. It also helps reduce the risk of heart-related events and is safe and well-tolerated.12345
Is Inclisiran safe for humans?
How does the drug inclisiran differ from other treatments for hypercholesterolemia?
Inclisiran is unique because it is a small interfering RNA drug that lowers cholesterol by blocking the production of a protein called PCSK9, which helps reduce bad cholesterol (LDL-C). Unlike other treatments, it is administered only twice a year, making it easier for patients to stick to their treatment plan.3491011
Research Team
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Eligibility Criteria
This trial is for children aged 2 to less than 12 with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing very high cholesterol. Participants must have genetically confirmed HoFH but can't join if they have certain mutations in both LDLR alleles.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment (Year 1)
Participants receive either inclisiran or placebo subcutaneous injections at Days 1, 90, and 270
Open-label Treatment (Year 2)
All participants receive inclisiran subcutaneous injections at Days 360, 450, and 630
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Inclisiran
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD